Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amoxicillin-clavulanic acid safety study in stable COPD
NL-OMON35569Active, not recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amoxicillin + clavulanate in chronic obstructive pulmonary disease (COPD), sponsored by Medisch Spectrum Twente. Primary endpoint: Safety and tolerability of inhaled nebulized amoxicillin-clavulanic acid. Started Feb 2012; status: active, not recruiting.
02
Drugs
amoxicillin + clavulanate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON35569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35569.